We are a holding company. (Incorporated in the Cayman Islands)

Our Hong Kong subsidiaries are active in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.

Based in Hong Kong, Joint Cross Border has established itself as a leading provider of third-party supply chain services in Mainland China’s OTC pharmaceutical cross-border e-commerce market. According to the Frost & Sullivan Report, we ranked first in this sector by revenue in 2022.

Through our engagement with OTC pharmaceutical suppliers, logistics companies, and merchants who operate stores on Chinese e-commerce platforms, Joint Cross Border offers a convenient one-stop solution for Mainland Chinese customers who wish to access OTC pharmaceutical products outside Mainland China. Joint Cross Border’s offering includes a comprehensive array of services such as pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting OTC pharmaceutical products to the Hong Kong Department of Health (“HKDOH”), obtaining import and export permits and clearances, storing products at warehouses, packaging, and arranging for logistics and end-to-end delivery services for consumers.

Note: Net income and revenue are for the fiscal year that ended March 31, 2024.

(Note: Hong Kong Pharma Digital Technology Holdings Limited filed its F-1 for its IPO on Oct. 29, 2024, and disclosed the terms: 1.5 million shares at a price range of $4.00 to $6.00 to raise $7.5 million. Background: Hong Kong Pharma Digital Technology submitted confidential IPO documents to the SEC on March 29, 2024.)